Cristina Csimma

Principal

United States of America

Cristina Csimma’s experience in the biopharmaceutical, venture capital and academic settings encompasses global development in multiple therapeutic areas including rare neuromuscular diseases, translational through registration clinical studies, and integration of biomarkers and novel technologies into development as well as leadership roles in new company formation and fund raising.

She was the founding CEO of Cydan Development, Inc., a privately held company focused on advancing the translation of therapeutics for orphan diseases and was previously Vice President of Drug Development at Virdante Pharmaceuticals Inc., Principal at Clarus Ventures LLC, held roles in Clinical Development and Translational Research at Wyeth (now Pfizer), Genetics Institute and Dana Farber Cancer Institute.

She serves on the Board of Directors of Neuralstem Inc. and Juniper Pharma; the Muscular Dystrophy Association Scientific Development Advisory Committee; the External Oversight Board to the National Institutes of Health (NIH) NeuroNext Network; the Steering Committee of NIH Blueprint Neurotherapeutics Network,  the Harvard and Brigham and Women’s Hospital MRCT Center External Advisory Board, and the Rockefeller University Robertson Therapeutic Development Fund Review. Previous appointments include Executive Chair of the Board of Directors of Exonics Therapeutics and Board Director of Vtesse Inc (acquired by Sucampo Pharmaceuticals).

Dr. Csimma received her Bachelor of Science and Doctor of Pharmacy degrees from Massachusetts College of Pharmacy, and a Master of Health Professions from Northeastern University.

Disclosure statement:

Cristina Csimma’s current industry appointments:

Neuralstem, Inc. – Board of Directors

Juniper Pharmaceuticals Inc – Board of Directors

Exonics Therapeutics – senior advisor

Italfarmaco – consultant